Precision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The ApoE4 allele is the most well-studied genetic risk factor for Alzheimer’s disease, a condition that is increasing in prevalence and remains without a cure. Precision nutrition targeting metabolic pathways altered by ApoE4 provides a tool for the potential prevention of disease. However, no long-term human studies have been conducted to determine effective nutritional protocols for the prevention of Alzheimer’s disease in ApoE4 carriers. This may be because relatively little is yet known about the precise mechanisms by which the genetic variant confers an increased risk of dementia. Fortunately, recent research is beginning to shine a spotlight on these mechanisms. These new data open up the opportunity for speculation as to how carriers might ameliorate risk through lifestyle and nutrition. Herein, we review recent discoveries about how ApoE4 differentially impacts microglia and inflammatory pathways, astrocytes and lipid metabolism, pericytes and blood–brain barrier integrity, and insulin resistance and glucose metabolism. We use these data as a basis to speculate a precision nutrition approach for ApoE4 carriers, including a low-glycemic index diet with a ketogenic option, specific Mediterranean-style food choices, and a panel of seven nutritional supplements. Where possible, we integrate basic scientific mechanisms with human observational studies to create a more complete and convincing rationale for this precision nutrition approach. Until recent research discoveries can be translated into long-term human studies, a mechanism-informed practical clinical approach may be useful for clinicians and patients with ApoE4 to adopt a lifestyle and nutrition plan geared towards Alzheimer’s risk reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 1×
“(For a more comprehensive recent review of microglia in AD, see Leng and Edison [35]).”
BackgroundKrasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 1×
“In mice, an ApoE protein-dependent pathway mediates the transition of microglia from a homeostatic to a DAM phenotype [37,38] and, correspondingly, the ApoE4 allele is associated with more reactive inflammatory microglia and worse tau pathology [39].”
BackgroundNLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 1×
“In mice, intracerebroventricular injections of small Aβ oligomers are sufficient to induce microglial activation [28], while inhibition of the NLRP3 inflammasome (an essential component of the DAM phenotype [29]) protects against amyloid-induced tauopathy and cognitive decline [30].”
BackgroundAlzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642 · cited 1×
“8 million by mid-century [2], imposing an unsustainable economic toll and an unimaginable human burden.”
BackgroundGenomic analysis of reactive astrogliosis
Zamanian, J. L., Xu, L., Foo, L. C., Nouri, N., Zhou, L., Giffard, R. G., & Barres, B. A. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6221-11.2012 · Cited by 2,404 · cited 1×
“This is notable in the context of DAA because obesogenic, inflammatory diets can induce NFκB and downstream markers of reactive astrocytes in model systems [41,43,44].”
BackgroundThe ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172
Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., Grueter, C. A., Lim, H., Saunders, L. R., Stevens, R. D., et al. (2013) · Science · doi:10.1126/science.1227166 · Cited by 1,777
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060900 · Cited by 1,729
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“Astrocytes are a center of lipid metabolism and cholesterol synthesis in the brain and its main producer of the lipoprotein ApoE4, coded by the ApoE4 allele [48].”
BackgroundNLRP3 inflammasome activation drives tau pathology
Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., et al. (2019) · Nature · doi:10.1038/s41586-019-1769-z · Cited by 1,487
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 1×
“More impressively, PET scan studies reveal that cognitively normal middle-aged ApoE4 carriers have impaired cerebral glucose metabolism, as compared to non-carriers, and in a dose-dependent manner [64,65].”
BackgroundApolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 2×
“Using transgenic mice, Bell and colleagues [55] showed that ApoE3 protein, but not ApoE4 protein, can bind to the LRP1 receptor to inhibit CypA expression and reduce downstream NFκB and MMP9 activity, protecting BBB integrity.”
BackgroundAPOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281 · cited 6×
“Pericytes influence blood–brain barrier (BBB) function [21] and it now appears that ApoE4 influences AD progression by directly altering vascular function [22].”
BackgroundInfluentialWilliamson (2019) · doi:10.1001/jama.2018.21442 · Cited by 1,246
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 1×
“In mice, an ApoE protein-dependent pathway mediates the transition of microglia from a homeostatic to a DAM phenotype [37,38] and, correspondingly, the ApoE4 allele is associated with more reactive inflammatory microglia and worse tau pathology [39].”
BackgroundType 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207
Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Wilson, R. S., Aggarwal, N., & Schneider, J. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.940 · Cited by 1,135
Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.008 · Cited by 1,125
Demographic Differences and Trends of Vitamin D Insufficiency in the US Population, 1988-2004
Ginde, A. A., Liu, M. C., & Camargo, C. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.604 · Cited by 1,120
Mediterranean diet and risk for Alzheimer's disease
Scarmeas, N., Stern, Y., Tang, M., Mayeux, R., & Luchsinger, J. A. (2006) · Annals of Neurology · doi:10.1002/ana.20854 · Cited by 1,103
Disease-associated astrocytes in Alzheimer’s disease and aging
Habib, N., McCabe, C., Medina, S., Varshavsky, M., Kitsberg, D., Dvir-Szternfeld, R., Green, G., Dionne, D., Nguyen, L., Marshall, J. L., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0624-8 · Cited by 1,009
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983 · cited 2×
“Turning to inflammation, βhB inhibits the formation of the NLRP3 inflammasome [92,93] that plays a critical role in the DAM phenotype and progression of amyloid and tau pathology in AD [30,31], as discussed above in the section on microglia.”
BackgroundKetone bodies as signaling metabolites
Newman, J. C., & Verdin, E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.002 · Cited by 966 · cited 1×
“βhB is an HDAC inhibitor [94,95], providing a mechanistic basis for βhB-mediated suppression of CypANFκB-MMP9 cascade via an increase in the pathway inhibitor, LRP1, which would also support Aβ clearance.”
BackgroundCholesterol metabolism in the brain
Dietschy, J. M., & Turley, S. D. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200104000-00003 · Cited by 906 · cited 1×
“The brain may only be 2% of the body’s mass, but it contains 25% of its cholesterol [51].”
BackgroundInsulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Advanced glycation end products contribute to amyloidosis in Alzheimer disease
Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., & Cerami, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4766 · Cited by 806 · cited 1×
“Furthermore, ApoE4 protein has 3-fold the binding affinity for advanced glycation end products (AGEs) [75], as compared to that of ApoE3, and AGEs are observed at threefold higher levels in the amyloid plaques of individuals with AD as compared to those from healthy controls [76].”
BackgroundMcKeown, N. M., Meigs, J. B., Liu, S., Saltzman, E., Wilson, P. W. F., & Jacques, P. F. (2004) · Diabetes Care · doi:10.2337/diacare.27.2.538 · Cited by 786 · cited 1×
“This can be achieved through low-glycemic index [68] or low-carbohydrate diets [69–71].”
BackgroundStreit, W. J., Braak, H., Xue, Q.-S., & Bechmann, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0556-6 · Cited by 727 · cited 1×
“Conversely, no evidence of DAM was observed in asymptomatic persons with increased amyloid levels [34].”
BackgroundThe aging astrocyte transcriptome from multiple regions of the mouse brain.
Boisvert, M. M., Erikson, G. A., Shokhirev, M. N., & Allen, N. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.039 · Cited by 702
Maphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff, R. M., Lamb, B. T., & Bhaskar, K. (2015) · Brain · doi:10.1093/brain/awv081 · Cited by 595 · cited 1×
“Prior studies have shown that reactive microglia drive tau pathology in animal models [26] and that reactive microglia are associated with tauopathy in humans [27].”
BackgroundAnstey, K. J., Mack, H. A., & Cherbuin, N. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181a2fd07 · Cited by 452
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
Leroy, K., Yilmaz, Z., & Brion, J. ‐. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00795.x · Cited by 404
ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism
Qi, G., Mi, Y., Shi, X., Gu, H., Brinton, R. D., & Yin, F. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108572 · Cited by 379 · cited 7×
“In brief, mechanisms exist whereby βhB could compensate for the defects in astrocyte–neuron lipid coupling described recently [20,54].”
BackgroundInfluentialMicroglial activation and amyloid deposition in mild cognitive impairment: A PET study
Okello, A., Edison, P., Archer, H. A., Turkheimer, F. E., Kennedy, J., Bullock, R., Walker, Z., Kennedy, A., Fox, N., Rossor, M., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000338622.27876.0d · Cited by 367
Yang, T., Li, S., Xu, H., Walsh, D. M., & Selkoe, D. J. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1698-16.2016 · Cited by 347
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
Riddell, D. R., Zhou, H., Atchison, K., Warwick, H. K., Atkinson, P. J., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1972-08.2008 · Cited by 346
Harris, F. M., Brecht, W. J., Xu, Q., Tesseur, I., Kekonius, L., Wyss-Coray, T., Fish, J. D., Masliah, E., Hopkins, P. C., Scearce-Levie, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1434398100 · Cited by 342
APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease
Michaelson, D. M. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.015 · Cited by 331
Athinarayanan, S. J., Adams, R. N., Hallberg, S. J., McKenzie, A. L., Bhanpuri, N. H., Campbell, W. W., Volek, J. S., Phinney, S. D., & McCarter, J. P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00348 · Cited by 324
Metabolic Reprograming of Microglia in the Regulation of the Innate Inflammatory Response
Lauro, C., & Limatola, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00493 · Cited by 315
Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes
Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Martens, Y. A., Linares, C., Knight, J. A., Painter, M. M., Sullivan, P. M., & Bu, G. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.003 · Cited by 289 · cited 4×
“Recall that Zhao and colleagues [23] found that the negative effects of ApoE4 on insulin resistance in their mice were accelerated by an obesogenic Western diet.”
BackgroundInfluentialGong, J.-S., Kobayashi, M., Hayashi, H., Zou, K., Sawamura, N., Fujita, S. C., Yanagisawa, K., & Michikawa, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203934200 · Cited by 214 · cited 3×
“In summary of its effects on lipid metabolism, (i) ApoE4 astrocytes have impaired ability to synthesize and secrete cholesterol [49,50], possibly contributing to an age-dependent cerebral cholesterol deficit.”
BackgroundInfluentialAssociation of Lithium in Drinking Water With the Incidence of Dementia
Kessing, L. V., Gerds, T. A., Knudsen, N. N., Jørgensen, L. F., Kristiansen, S. M., Voutchkova, D., Ernstsen, V., Schullehner, J., Hansen, B., Andersen, P. K., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2362 · Cited by 213
Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss
Hyde, P. N., Sapper, T. N., Crabtree, C. D., LaFountain, R. A., Bowling, M. L., Buga, A., Fell, B., McSwiney, F. T., Dickerson, R. M., Miller, V. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128308 · Cited by 210 · cited 1×
“showed that, even when total and saturated dietary fat intakes are increased by 2–3-fold, serum triglycerides and serum saturated fat still decreased relative to isocaloric higher-carbohydrate, lower-fat diets [70].”
BackgroundLin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.011 · Cited by 210 · cited 2×
“Furthermore, CRISPR/Cas9-mediated conversion of human iPSC-derived microglia from ApoE3 to isogenic ApoE4 is associated with a change in the expression of 1460 genes, in association with impaired ability to clear Aβ42 and an inflammatory transcriptomic signature [40].”
BackgroundAmyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH
Prasad, H., & Rao, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801612115 · Cited by 207 · cited 16×
“(LRP1 is also helps to inhibit the CypA-NFκB-MMP9 pathway, discussed below).”
BackgroundResultInfluentialWu, L., Zhang, X., & Zhao, L. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.2262-17.2018 · Cited by 185 · cited 13×
“This is particularly notable in the ApoE4 context because ApoE4, as compared to ApoE3, exhibits reduced glucose metabolic capacity; however, this can be rescued by increasing PGC1α expression in model systems [82].”
BackgroundInfluentialAstrocytic ApoE reprograms neuronal cholesterol metabolism and histone-acetylation-mediated memory
Li, X., Zhang, J., Li, D., He, C., He, K., Xue, T., Wan, L., Zhang, C., & Liu, Q. (2021) · Neuron · doi:10.1016/j.neuron.2021.01.005 · Cited by 165 · cited 5×
“In brief, mechanisms exist whereby βhB could compensate for the defects in astrocyte–neuron lipid coupling described recently [20,54].”
BackgroundInfluentialApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes
Rawat, V., Wang, S., Sima, J., Bar, R., Liraz, O., Gundimeda, U., Parekh, T., Chan, J., Johansson, J. O., Tang, C., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1400-19.2019 · Cited by 165 · cited 2×
“(ii) ApoE4 decreases surface ABCA1 levels, resulting in impaired ApoE lipidation and lipid trafficking [53].”
BackgroundPartsalaki, Karvela, A., & Spiliotis, B. E. (2012) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2012-0131 · Cited by 107
Vascular ApoE4 impairs behavior by modulating gliovascular function
Yamazaki, Y., Liu, C.-C., Yamazaki, A., Shue, F., Martens, Y. A., Chen, Y., Qiao, W., Kurti, A., Oue, H., Ren, Y., et al. (2021) · Neuron · doi:10.1016/j.neuron.2020.11.019 · Cited by 71
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“These components have been shown to increase LRP1 and ABCA1 levels, decrease NFκB and MMP9 activity, and increase brain docosahexaenoic acid (DHA) levels [264].”
BackgroundFernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Wei, B.-Z., Li, L., Dong, C.-W., Tan, C.-C., & Xu, W. (2023) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.04.001 · Cited by 169
A Review of ApoE4 Interference Targeting Mitophagy Molecular Pathways for Alzheimer's Disease
Chen, H., Chen, F., Jiang, Y., Zhang, L., Hu, G., Sun, F., Zhang, M., Ji, Y., Chen, Y., Che, G., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.881239 · Cited by 19
Metadata
- Authors
- Norwitz, N. G., Saif, N., Ariza, I. E., & Isaacson, R. S.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2021-04-19
- Volume
- 13
- Issue
- 4
- Pages
- 1362
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W3153578599
- Cited by
- 85
- References
- 55
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.